Clinical trial insurance protects participants and the sponsor if someone is injured as a result of taking part in a study. In many countries it is a legal requirement, and ethics committees will not approve a trial without a valid certificate. In the United States there is no federal mandate, but institutions routinely require evidence of coverage and subject injury terms in their contracts. First-time sponsors often discover these requirements late, when they are already on the critical path to first patient.
What does clinical trial insurance cover?
A clinical trial liability policy typically covers the sponsor's legal liability for bodily injury to participants arising from the trial, including legal defense costs. Some policies, and some national schemes, also provide compensation on a no-fault basis, meaning a participant can receive compensation without proving negligence. The exact coverage, limits, and exclusions vary by insurer and by country, which is why the policy wording deserves careful review rather than a quick signature.
Is clinical trial insurance required?
It depends on where the study runs. Under the EU Clinical Trials Regulation, each member state must have a system for compensating participants for damage, in the form of insurance, a guarantee, or a similar arrangement, and national rules set the details. Many other countries have their own mandatory requirements. In the United States, FDA's informed consent regulation at 21 CFR 50.25(a)(6) requires that consent for research involving more than minimal risk explain whether any compensation and medical treatment are available if injury occurs, and sites expect the sponsor to stand behind that language.
When does insurance need to be in place?
Earlier than most sponsors plan for. In countries that require it, the insurance certificate is part of the ethics or regulatory submission, so it must exist before you file. Site contracts also tend to stall until institutions see proof of coverage. For a multinational study, arranging local policies through locally admitted insurers can take several weeks, so the work should start alongside CRO selection.
What drives the cost of coverage?
Underwriters consider the number of participants, the countries involved, the phase and risk profile of the study, the type of investigational product, and the minimum limits required in each country. A first-in-human study generally carries more uncertainty than a later-phase study of a well-characterized product. Expanding to new countries or adding participants during the study usually requires notifying the insurer and may change the premium.
How does insurance connect to site contracts?
Clinical trial agreements typically include subject injury provisions describing what the sponsor will pay for if a participant is harmed, along with indemnification terms and insurance requirements. Those terms need to align with your policy limits and with the language in the informed consent form. Misalignment between the three is a common reason contract negotiations with institutions take longer than expected.
Who arranges the policy, the sponsor or the CRO?
The sponsor normally holds the policy, because the liability is the sponsor's. A CRO can be very helpful in identifying country-specific requirements and in collecting certificates for submissions, but the sponsor should engage a broker experienced in life sciences clinical trial coverage and own the decision about limits and wording.
Which gaps catch first-time sponsors?
The same handful appear again and again:
Assuming a general corporate liability policy covers clinical trials, which it often does not
Missing a local policy when a new country is added
Limits below a country's statutory minimum
A policy period that ends before long-term follow-up is complete
Subject injury language in the informed consent form that does not match the site contract or the policy
Keep reading: What US Biotechs Should Know About the EU Clinical Trials Regulation
